Original research

The spectrum of non-fatal immune-related adverse events following COVID-19 vaccination: The population-based cohort study in Seoul, South Korea

Authors:

Jee Hyun Suh, MD, PhD[1, †], Hong Jin Kim, MD, PhD[2, †], Min-Ho Kim, PhD[3], Myeong Geun Choi, MD, PhD[4], Eun Mi Chun, MD, PhD[4, *]

Affiliations:

[1]Department of Rehabilitation Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.

[2]Department of Orthopedic Surgery, Inje University Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea

[3]Informatization Department, Ewha Womans University Seoul Hospital, Seoul 07804, Republic of Korea

[4]Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul, Republic of Korea

[†]Jee Hyun Suh, MD, PhD, and [†]Hong Jin Kim, MD, PhD equally contributed to this study as the co-first author.

[*]**Contact information for the corresponding author:** Eun Mi Chun, MD, PhD

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University, 1071, Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Republic of Korea (e-mail: cem@ewha.ac.kr)

Tel.: 82-2-2650-2869, Fax: 82-2-2650-6176, ORCID ID: https://orgid.org/0000-0001-9616-2722

Abstract

Objective: To examine the incidence rate and risk of non-fatal irAEs, including gynecological, hematological, dermatological, ophthalmological, otologic, and dental problems following the COVID-19 vaccination.

Methods: We conducted a population-based cohort study from the National Health Insurance Service (NHIS) database in Seoul, South Korea. The non-fatal irAEs included gynecological, hematological, dermatological, ophthalmological, ear, and periodontal problems as reported by the Vaccine Adverse Event Reporting Center. The cumulative incidence rate per 10,000 population, Odds ratio, and Hazard ratio (HR) with 95% Confidence Interval (CI) were measured to assess the non-fatal irAEs after COVID-19 vaccination.

Results: The cIR of non-fatal irAEs for three months was significantly higher in vaccinated subjects than in non-vaccinated subjects, except for endometriosis. The vaccination significantly increased the risks of all the non-fatal irAEs except for visual impairment. The risk of inner ear disease showed the highest HRs (HR [95% CI] = 2.368 [2.153-2.604]) among the non-fatal irAEs following COVID-19 vaccination. Among the vaccinated subjects, heterologous vaccination was associated with the increased risk of most of the non-fatal irAEs.

Conclusions: The three-month risks of incidental non-fatal irAEs are substantially higher in the COVID-19 vaccinated subjects than in non-vaccinated controls. Our findings suggested that vaccinated subjects with predisposition are potentially vulnerable to the occurrence of diverse irAEs although the COVID-19 vaccines may not be fatal.

Introduction

Coronavirus disease-2019 (COVID-19), as a global challenge for health and socioeconomic issues, demonstrated a subsequent rise in morbidity and mortality in the early stages of the pandemic compared to other viral infections.[1] With the rapid development of vaccines in response to the unprecedented COVID-19 pandemic, there has been a contribution in the reduction of the severity and fatality rates. Subsequently, several types of vaccines after approval of the AZD1222 vaccine have been released to prevent COVID-19 infection.[2-5] However, a wide range of adverse events (AEs), not previously reported in conventional vaccines, have been observed post-vaccination.[6-8]

As every country has done, South Korea initiated the COVID-19 vaccination program at care facilities and subsequently expanded its coverage to encompass the entire nation's population. About 80% of the population in South Korea was vaccinated within a year, which contributed to a significant decrease in COVID-19 infection.[9] Meanwhile, there is increasing evidence that many vaccinated populations could experience several unexpected complications, such as immune-related AEs (irAEs).[6-8 10 11] Many post-vaccination AEs are believed to originate from an immune response characterized by an inflammatory cytokine storm that causes irreversible damage to the cardiovascular, cerebrovascular, and respiratory systems.[12 13] Much of the current literature on the side effects occurring after the COVID-19 vaccination focused on serious AEs such as cardiovascular complications. Consequently, the non-fatal irAEs have yet to be comprehensively elucidated.[11 14-20] Therefore, this study aims to assess the non-fatal irAEs after COVID-19 vaccination from the National Health Insurance Service (NHIS) database in Seoul, South Korea.

Methods

Data source

This from the Korean National Health Insurance Service (NHIS) database on 1, January 2021 enrolled randomly extracted 50% of individuals residing in Seoul, South Korea. We randomly selected 50% of the residents living in Seoul as of January 1, 2021, and obtained their diagnostic records from 2020 to 2021. The International Classification of Diseases, 10th revision (ICD-10), was adopted by the NHIS to classify disease diagnoses. The data included the primary diagnosis, secondary diagnosis, and dates of hospital visits. This population-based

cohort study was conducted by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.[21]

Study population

A total of 4 348 412 individuals living in Seoul, constituting 50% of the population, were included and investigated as of January 1, 2021. Individuals aged under 20 years were excluded, leaving 4 203 887 individuals for analysis. In this study, only individuals who had received two doses of COVID-19 vaccine were included in the vaccinated group. In this cohort study, the index date, which is the date on which individuals started participating in the study, was set differently for the vaccinated and non-vaccinated groups. For the vaccinated group, the index date was set as the date of the second vaccine dose administered before September 30, 2021. On the other hand, for the non-vaccinated group, the index date was set as October 1, 2021. The history of COVID-19 vaccination was investigated as of January 1, 2021. On January 1, 2021, the vaccinated group included 3 839 014 individuals, whereas the non-vaccinated group included 364,873 individuals. Individuals who received a dose of vaccine before January 1, 2021, and did not receive a second dose between January 1, 2021, and September 30, 2021, were excluded. The vaccinated group included 2 154 389 individuals, whereas the non-vaccinated group included 350,953 individuals.

The non-fatal irAEs included gynecological (endometriosis, and menstrual disorders [polymenorrhagia, menorrhagia, abnormal cycle length, oligomenorrhea, and amenorrhea]), hematological (bruises confined to nontender and yellow-colored on especially extremities), dermatological (herpes zoster, alopecia, and warts), ophthalmological (visual impairment, and glaucoma), otological (tinnitus, inner ear, middle ear, and outer ear disease), and dental problems (periodontal disease) as reported by the Vaccine Adverse Event Reporting Center. To investigate the causal relationship between vaccine administration and irAEs, the diagnostic records for a year before the index date were traced. Individuals with any target disease as a primary or secondary diagnosis during this period were excluded from the study. The occurrence of the target disease was defined as receiving a primary diagnosis of the disease from the day after the index date.

Outcome measurements

The primary outcome measure was cumulative incidence rates (cIRs) of irAEs per 10,000 population between the vaccinated and non-vaccinated subjects. The cIRs of the irAEs were measured at one week, two weeks, one month, and three months. The secondary outcome measures were the odd ratios (ORs) and hazard ratios (HRs) of irAEs. Furthermore, subgroup analyses were also conducted based on gender, the number of COVID-19 vaccine doses, the vaccine type (mRNA vaccine, cDNA vaccine, and heterologous vaccination), health insurance level, presence of diabetes mellitus (DM), hypertension (HTN), hyperlipidemia, and chronic obstructive pulmonary disease (COPD).

Age, gender, insurance level, Charlson's comorbidity index (CCI), presence of DM, HTN, hyperlipidemia, and COPD, and prior COVID-19 infection history were extracted using their ICD-19 codes, which were suggested by Sundararajan et al.[22] The presence of comorbid diseases (i.e. DM, HTN, hyperlipidemia, and COPD), items in CCI, and the prior COVID-19 infection history was determined as a primary or secondary diagnosis 2 or more times within 1 year before the index date. The NHI premium was used as a proxy measure of income because it is proportional to monthly income, including earnings and capital gains. The income quantiles of the enrolled individuals were categorized into three groups (low-, middle- and high-income groups in medical aid enrollees and the 0–33, 34–66, and 67–100 centiles of NHI enrollees).

Statistical analysis

Statistical analysis was performed using SAS Enterprise Guide (version 8.3., SAS Institute, Cary, NC, USA). A normal distribution was confirmed with the Kolmogorov–Smirnov test. Baseline patient characteristics and comorbidities were reported as means ± standard deviation for continuous variables and frequency (percentage, %) for categorical variables. Student's t-test was performed for continuous variables, and the chi-square test or immune-mediated adverse events associated with COVID-19 vaccination were assessed using Student's t-test for continuous variables, and the chi-square test or Fisher's exact test for categorical variables. The cIR was calculated per 10,000 populations. To identify the association between COVID-19 vaccination and irAEs, a multiple logistic regression model was used for ORs, corresponding to 95% CIs. Cox proportional hazards regression was used to estimate the HRs and 95% CIs. Two-sided *P* values of 0.05 or less were considered to indicate statistical significance

Results

The participants' characteristics

In total, 1 748 136 subjects were included in this study. Among them, 289 579 (16.57 %) had not received the Covid-19 vaccine (i.e. non-vaccinated subjects), whereas 1 458 557 (83.43 %) were vaccinated against COVID-19 (i.e. vaccinated subjects) (**Figure 1**). The baseline characteristics of the vaccinated and non-vaccinated groups are shown in **Table 1**.

The cIRs per 10,000 of the non-fatal irAEs following the COVID-19 vaccination

Among the non-fatal irAEs in this study, the cIRs at three months following COVID-19 vaccination were higher in vaccinated subjects than in non-vaccinated subjects, except for endometriosis. The highest cIR of the non-fatal irAEs in vaccinated subjects was observed in other ear diseases (cIR, 51.78%; 95% CI, 50.61-52.94) followed by inner ear diseases (cIR, 47.10%; 95% CI, 45.99-48.21), herpes zoster (cIR, 45.08%; 95% CI, 43.99-46.17), menstrual disorders (cIR, 44.43%; 95% CI, 43.35-45.51), and glaucoma (cIR, 39.42%; 95% CI, 38.40-40.43). Among the non-fatal irAEs, 50% exhibited a significant difference in cIRs one-week post-vaccination. Menstrual disorders and visual impairments were noted from one-month, whereas alopecia, warts, and periodontal disease were observed from two weeks onwards (**Table 2)**.

When stratified by gender, the cIRs of irAEs showed a similar pattern to that of the overall population. At three months post-vaccination, menstrual disorders presented the highest cIRs in females (cIR, 87.54%; 95% CI, 85.41-89.66) followed by inner ear diseases in females (cIR, 62.82%; 95% CI, 61.02-64.62), other ear diseases in females (cIR, 55.27%; 95% CI, 53.58-56.96), and herpes zoster in females (cIR, 53.13%; 95% CI, 51.48-54.79). When stratified by vaccine type, heterologous vaccination increased the cIR of menstrual disorders to 78.96% (95% CI, 73.45-84.48). The detailed cIRs stratified by gender or vaccine type were presented in **Supplement tables S1 and S2**.

The risks of non-fatal irAEs following the COVID-19 vaccination

In the Cox proportional hazard model in this study, COVID-19 vaccination significantly increased the risks of non-fatal AEs except for visual impairments (HR, 3.935; 95% CI, 0.943-16.410), with the highest level of alopecia (HR, 2.397; 95% CI, 1.896-3.029) followed by inner ear diseases (HR, 2.368; 95% CI, 2.153-2.604), and herpes zoster (HR, 2.337; 95% CI, 2.122-2.573) **(Figure 2a)**. In the multivariate logistic model in this study, the COVID-19 vaccination was associated with a significant increase in the risk of most non-fatal irAEs, indicating potential influence in the early time point (one-week after COVID-19 vaccination). At three months post-vaccination, the COVID-19 vaccination significantly increased the risk of endometriosis (OR, 1.631; 95% CI, 1.313-2.025). Furthermore, visual impairment at three months (OR, 3.956; 95% CI, 0.949-16.496), tinnitus at one-week (OR, 1.840; 95% CI, 0.981-3.451), and two weeks (OR, 1.513; 95% CI, 1.000-2.287), and periodontal diseases at one-week (OR, 0.965; 95% CI, 0.366-2.546), two weeks (OR, 1.771; 95% CI, 0.760-4.126), and one-month (OR, 1.662; 95% CI, 0.955-3.041) showed no statistical differences of ORs between two groups **(Figure 2b)**. The detailed data for risks of non-fatal irAEs following the COVID-19 vaccination were described in **Supplement Tables S3 and S4**.

The risks of non-fatal irAEs according to the COVID-19 vaccine type

Both the multivariate logistic regression model and the Cox proportional hazard model were used to assess the risk factors according to the COVID-19 vaccine type **(Figure 3)**. In the Cox proportional hazard model, heterologous vaccination was more increased the risks of gynecological problems including endometriosis (HR, 2.784; 95% CI, 2.083-3.722]) and menstrual disorders (HR, 2.837; 95% CI, 2.583-3.117]), hematological problem including bruise (HR, 1.891; 95% CI, 1.208-2.962), dermatological problems including herpes zoster (HR, 2.894; 95% CI, 2.153-2.604) and alopecia (HR, 3.413; 95% CI, 2.520-4.623), ophthalmological problem including glaucoma (HR, 1.828; 95% CI, 1.596-2.093), and periodontal diseases (HR, 3.560; 95% CI, 2.179-5.818) compared to other types of vaccination **(Figure 3a)**. In the multivariate logistic regression model, most trends of risks were shown a similar pattern to that of Cox proportional hazard models. According to time points, alopecia and periodontal diseases were associated with the highest risk outcomes following heterologous vaccinations compared to other vaccination methods. However, vaccination using cDNA only was observed to notably increase risks of bruise at one-week (OR [95% CI] = 5.767 [2.010-16.543]), two weeks (HR, 6.260; 95% CI, 2.280-14.621),

and one-month (HR, 4.996; 95% CI, 2.659-9.388]) **(Figure 3b)**. The detailed data was presented in **Supplement tables S5 and S6**.

Discussion

The concerns for post-sequelae and vaccine-related complications have been raised as one of the global important issues.[1 9] The main focus of the COVID-19 vaccine-related complications were serious AEs such as cardiovascular, and neurological problems that can give rise to fatal conditions.[6 7] To the best of our knowledge, the research regarding non-fatal irAEs following COVID-19 vaccination did not conduct a large population-based cohort study at the nationwide level.[10] Here, we investigated the 14 non-fatal irAEs following COVID-19 vaccination in Seoul, South Korea. By comparing the 1 458 557 vaccinated subjects and 289 579 non-vaccinated subjects, we found that 13 non-fatal irAEs except for endometriosis showed a significant increase in cumulative incidence following COVID-19 vaccination with notable significant higher rates of menstrual disorders, herpes zoster, glaucoma, inner ear diseases, middle ear diseases, and other ear disease than in non-vaccinated subjects. Furthermore, bruise is associated with COVID-19 vaccination in the early phase showing the highest ORs at one-week and two weeks. For three months follow-up, alopecia showed the highest level of HRs following COVID-19 vaccination.

The type of vaccination has been associated with immune response given cellular mechanisms.[13 23] Lee et al. showed that heterologous vaccination leads to enriched B cells and $CD4^+$ T cell responses with higher activation of interferon pathways, suggesting the potential increase of ir AEs.[24] In this study for non-fatal irAEs, heterologous vaccination showed the highest risks of eight irAEs including endometriosis, menstrual disorders, bruise, herpes zoster, alopecia, glaucoma, and periodontal diseases compared to other types of vaccination. Thus, Peripheral blood and skin lesions may exhibit heightened immune responses following heterologous vaccination.

The spike protein is considered a primary target for the development of vaccines against COVID-19 because the infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is initiated by the binding of spike protein to the ACE2 receptor on the host cell surface.[23 25] Yonker et al. suggested that the circulating spike protein were detected in peripheral blood of patients who developed post-mRNA vaccine myocarditis.[25] Several studies, supporting Yonker et al., provide potential insight into the possibility that mRNA-LNP can act as a potential underlying cause for diverse irAEs.[25-28] The main difference between cDNA-based vaccines and mRNA-based vaccines against SARS-CoV-2 was mediators of immune responses, which were

respectively spike protein and lipid-nanoparticle-encapsulated mRNA.[23] The current hypothesis between COVID-19 vaccination and ear diseases as AEs is that the ear disease is activated by intensification of a spike protein-specific IgG and potential systematic immune response suggesting the immunologic important factors.[29] Surprisingly, in this study, most ear problems including tinnitus, inner ear disease, and middle ear diseases showed the highest HRs in vaccination using cDNA only compared to other types of vaccination. The findings of this study are not only consistent with existing hypotheses indicating the important role of spike protein in SARS-CoV-2.

For gynecological and hematological issues, previous studies have suggested that the COVID-19 vaccination increased bleeding from the changes in the irregular menstrual cycle. [30] Population-based studies reported that unexpected vaginal bleeding and menstrual bleeding changes as emerging phenomenon.[27] [28] Likewise, our study also showed that increased cIRs and risks of menstrual disorders (including menorrhagia, metrorrhagia, and hypermenorrhea), and bruises (vaccine-specific manifestation, i.e. non-tender yellow-colored bruises on especially extremities), which significantly rose on heterologous vaccinations. One of the important points for this result was the trend of the diminishing risk of bruises after vaccination. Considering previous studies, these manifestations were caused by hormonal changes resulting from spike proteins and disruption of coagulation pathway in endometrium.[27] [28] Thus, both clinicians and vaccinated subjects need to be cautious of bruise occurrence within one-month post-vaccination. In addition, vaccination using cDNA only significantly increased the risks of bruises very significantly at the early phase compared to other types so special caution may be needed in the vaccinated subjects using cDNA vaccine up to at least two weeks post-vaccination. While there were no significant differences in cIR of endometriosis at three months between vaccinated and non-vaccinated subjects, this study revealed an increased risk of endometriosis associated with COVID-19 vaccination at the three months post-vaccination. These results suggest that the cIR of endometriosis may see a significant rise beyond three months, indicating the need for extended long-term follow-up studies.

Strengths and Limitations

Our study has several strengths and potential limitations for non-fatal AEs following COVID-19 vaccination. First, many non-fatal irAEs have been reported as case reports or case series so it is the first study to investigate non-fatal irAEs following COVID-19 vaccination.[14] [15] [20] [29] [31] For diverse manifestations including post-vaccination

glaucoma, ear diseases, and alopecia, these irAEs shared potential pathophysiological mechanisms as expression of spike proteins, which dysregulate immunity, lead to molecular mimicry phenomena, and activate the pro-inflammatory cytokines.[13 15] With the suggested mechanisms in the literature, our studies are consistent with this hypothesis because the types of vaccinations have higher HRs in heterologous or cDNA vaccination compared to mRNA-only vaccination. Second, the current studies have been demonstrated that the COVID-19 vaccine effect on T cell mediated immune response in multiple sclerosis, which lead to autoimmunity.[19] Our findings for the spectrum of non-fatal irAEs strengthens their studies sharing the similar pathophysiological mechanisms and hypothesis such as role of spike proteins and autoimmune diseases triggered by vaccines. Last, the non-fatal irAEs after COVID-19 vaccination are relatively common and can be affected by various factors such as vaccination methods.[19] Furthermore, our findings also suggest that different types of vaccinations exhibit distinct activation patterns at various sites, which will need to be studied in future. Even in case, the warts on cheek was developed with positive for spike IgG and negative for nucleocapsid IgG after mRNA-based vaccination, suggesting that the mRNA-LNP triggers autoimmune response.[18] Therefore, the COVID-19 vaccines may not be fatal, but vaccinated people with predisposition may more susceptible for occurrence of AEs. Furthermore, our study indicate that it is essential to consider potential side effects that persist beyond three months. As the toxicity of COVID-19 diminishes and a significant portion of the worldwide population acquires natural immunity, it is important to designate as vaccine recipients those for whom the benefits of vaccination outweigh the potential side effects for ongoing vaccination.

Conclusions

The three-month risks of incidental non-fatal irAEs are substantially higher in the COVID-19 vaccinated subjects than in non-vaccinated controls. Our findings suggested that vaccinated subjects with predisposition are potentially vulnerable to the occurrence of diverse irAEs although the COVID-19 vaccines may not be fatal. Consequently, clinicians should maintain closed observation of a range of non-fatal irAEs after vaccination, given that these manifestations might emerge post-vaccination.

Summary boxes

What is already known on this topic

- Although the COVID-19 vaccines have been shown to have favorable safety and efficacy, they have also been associated with adverse events (AEs) stemming from immune-related responses.
- Much of the current literature on COVID-19 vaccination focused on serious AEs but the various non-fatal immune-related adverse events (irAEs) have yet to be comprehensively elucidated.

What this study adds

- In a population-based cohort study of 1,748,136 participants in Seoul, South Korea, the three-month cumulative incidence rates of non-fatal irAEs were significantly higher in vaccinated subjects than in non-vaccinated subjects. The vaccination significantly increased the risks of non-fatal irAEs following COVID-19 vaccination.
- The findings of this study suggest that clinicians should maintain closed observation of a range of non-fatal irAEs after vaccination, given that these manifestations might emerge post-vaccination.

How this study might affect research, practice or policy

- This population-based study suggested that vaccinated subjects with predisposition are potentially vulnerable to the occurrence of diverse irAEs although the COVID-19 vaccines may not be fatal.

Ethical Statement

The study protocol was approved by the Institutional Review Board of our institute (IRB No.: EUMC 2022-07-003), which waived the requirement for informed consent because data analyses were performed retrospectively using anonymized data derived from the South Korean NHIS database.

Acknowledgment

None

Footnotes

Contributors: EMC conceptualized the study. JHS, M-HK, and EMC designed the study. JHS, HJK, M-HK, and EMC analyzed and interpreted the data. M-HK acquired the data. JHS, HJK, and EMC drafted the manuscript. JHS, HJK, M-HK, MGC, and EMC critically reviewed the work. MGC verified the data in the study. All authors had full access to all the data and had final responsibility for the decision to submit for publication.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of Interest: The authors have no conflicts of interest to report.

References

1. Gupta A, Madhavan MV, Sehgal K, *et al*. Extrapulmonary manifestations of COVID-19. *Nat Med* 2020;26:1017-32. doi: 10.1038/s41591-020-0968-3.
2. Feikin DR, Higdon MM, Abu-Raddad LJ, *et al*. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* 2022;399:924-44. doi: 10.1016/S0140-6736(22)00152-0.
3. Voysey M, Clemens SAC, Madhi SA, *et al*. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;397:99-111. doi: 10.1016/s0140-6736(20)32661-1.
4. Baden LR, El Sahly HM, Essink B, *et al*. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021;384:403-16. doi: 10.1056/NEJMoa2035389.
5. Thomas SJ, Moreira ED, Jr., Kitchin N, *et al*. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* 2021;385:1761-73. doi: 10.1056/NEJMoa2110345.
6. Patone M, Handunnetthi L, Saatci D, *et al*. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. *Nat Med* 2021;27:2144-53. doi: 10.1038/s41591-021-01556-7.
7. Wang W, Wang CY, Wang SI, *et al*. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. *EClinicalMedicine* 2022;53:101619. doi: 10.1016/j.eclinm.2022.101619
8. Cho JY, Kim KH, Lee N, *et al*. COVID-19 vaccination-related myocarditis: a Korean nationwide study. *Eur Heart J* 2023;44:2234-43. doi: 10.1093/eurheartj/ehad339.
9. Jung J. Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications. *J Korean Med Sci* 2021;36:e59. doi: 10.3346/jkms.2021.36.e59.
10. Lee DS, Kim JW, Lee KL, *et al*. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study. *Int J Infect Dis* 2022;118:173-82. doi: 10.1016/j.ijid.2022.03.007.
11. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, *et al*. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. *J Neurol Sci* 2021;428:117607. doi: 10.1016/j.jns.2021.117607.

12. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, *et al*. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nat Med* 2021;27:270-78. doi: 10.1038/s41591-020-01194-5.

13. Li C, Lee A, Grigoryan L, *et al*. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. *Nat Immunol* 2022;23:543-55. doi: 10.1038/s41590-022-01163-9.

14. Singh RB, Parmar UPS, Kahale F, *et al*. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis. *Ophthalmology* 2023;130:179-86. doi: 10.1016/j.ophtha.2022.08.027.

15. Wichova H, Miller ME, Derebery MJ. Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience. *Otol Neurotol* 2021;42:e1213-e18. doi: 10.1097/mao.0000000000003275.

16. Fazlollahi A, Zahmatyar M, Noori M, *et al*. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. *Rev Med Virol* 2022;32:e2318. doi: 10.1002/rmv.2318.

17. Genco L, Cantelli M, Noto M, *et al*. Alopecia Areata after COVID-19 Vaccines. *Skin Appendage Disord* 2023;9:141-43. doi: 10.1159/000528719.

18. Cazzato G, Romita P, Foti C, *et al*. Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation? *Vaccines (Basel)* 2022;10. doi: 10.3390/vaccines10040532.

19. Toljan K, Amin M, Kunchok A, *et al*. New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure. *J Neuroimmunol* 2022;362:577785. doi: 10.1016/j.jneuroim.2021.577785.

20. Gallo G, Mastorino L, Tonella L, *et al*. Alopecia areata after COVID-19 vaccination. *Clin Exp Vaccine Res* 2022;11:129-32. doi: 10.7774/cevr.2022.11.1.129.

21. von Elm E, Altman DG, Egger M, *et al*. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370:1453-7. doi: 10.1016/s0140-6736(07)61602-x.

22. Sundararajan V, Henderson T, Perry C, *et al*. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol* 2004;57:1288-94. doi: 10.1016/j.jclinepi.2004.03.012.

23. Seyed Hosseini E, Riahi Kashani N, Nikzad H, *et al*. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. *Virology* 2020;551:1-9. doi: 10.1016/j.virol.2020.08.011.

24. Lee HK, Go J, Sung H, *et al*. Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron. *iScience* 2022;25:104473. doi: 10.1016/j.isci.2022.104473.

25. Yonker LM, Swank Z, Bartsch YC, *et al*. Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis. *Circulation* 2023;147:867-76. doi: 10.1161/CIRCULATIONAHA.122.061025

26. Ndeupen S, Qin Z, Jacobsen S, *et al*. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. *iScience* 2021;24:103479. doi: 10.1016/j.isci.2021.103479.

27. Blix K, Laake I, Juvet L, *et al*. Unexpected vaginal bleeding and COVID-19 vaccination in nonmenstruating women. *Sci Adv* 2023;9:eadg1391. doi: 10.1126/sciadv.adg1391.

28. Lee KMN, Junkins EJ, Luo C, *et al*. Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. *Sci Adv* 2022;8:eabm7201. doi: 10.1126/sciadv.abm7201.

29. Ciorba A, Corazzi V, Bianchini C, *et al*. Autoimmune inner ear disease (AIED): A diagnostic challenge. *Int J Immunopathol Pharmacol* 2018;32:2058738418808680. doi: 10.1177/2058738418808680.

30. Farland LV, Khan SM, Shilen A, *et al*. COVID-19 vaccination and changes in the menstrual cycle among vaccinated persons. *Fertil Steril* 2023;119:392-400. doi: 10.1016/j.fertnstert.2022.12.023.

31. Su YW, Yeh SJ, Chen MJ. New-onset Glaucoma Following Moderna COVID-19 Vaccination. *J Curr Glaucoma Pract* 2023;17:106-09. doi: 10.5005/jp-journals-10078-1408.

Figure legends

Figure 1. Flowchart of this study

Figure 2. The risk for non-fatal autoimmune-related adverse events (irAEs) by COVID-19 vaccination. a. Cox proportional hazard model, which is presented as a forest plot (hazard ratio [red circle] with 95% confidence interval [bar]). If clinical significance, it is marked as red-bar. b. Multivariate logistic regression model along with time point, which presented as forest plot (odd ratio [red circle] with 95% confidence interval [bar]).

Figure 3. The risk for non-fatal autoimmune-related adverse events (irAEs) of vaccinated subjects according to vaccine type. a. Cox proportional hazard model, which is presented as a forest plot (hazard ratio [red circle] with 95% confidence interval [bar]). If clinical significance, it is marked as red-bar. b. Multivariate logistic regression model along with time point was presented as the odd ratio of a heatmap. If clinical significance, it is marked as *.

Table 1 Baseline characteristics of the patients stratified by COVID-19 vaccination in South Korea.

	Total (n=1,748,133)	**Vaccination**		***P***
		No (n=289,576)	**Yes (n=1,458,557)**	
Gender, n (%)				
Male	861,301 (49.27%)	143,128 (49.43%)	718,173 (49.24%)	.064
Female	886,832 (50.73%)	146,448 (50.57%)	740,384 (50.76%)	
Age, mean (SD), years	53.32 (16.87)	45.00 (16.89)	54.97 (16.37)	
20 – 29 years, n (%)	21,3267 (12.20%)	54,748 (18.91%)	158,519 (10.87%)	
30 – 39 years, n (%)	191,879 (10.98%)	72,852 (25.16%)	119,027 (8.16%)	<.001*
40 – 49 years, n (%)	231,285 (13.23%)	63,163 (21.81%)	168,122 (11.53%)	<.001
50 – 59 years, n (%)	430,101 (24.60%)	42,637 (14.72%)	387,464 (26.56%)	
60 – 69 years, n (%)	398,344 (22.79%)	28,757 (9.93%)	369,587 (25.34%)	
70 – 79 years, n (%)	190,087 (10.87%)	13,351 (4.61%)	176,736 (12.12%)	
≥ 80 years, n (%)	93,170 (5.33%)	14,068 (4.86%)	79,102 (5.42%)	
Insurance level, n (%)				
Low	449,717 (25.73%)	85,471 (29.52%)	364,246 (24.97%)	<.001
Moderate	492,107 (28.15%)	91,292 (31.53%)	400,815 (27.48%)	
High	806,309 (46.12%)	112,813 (38.96%)	693,496 (47.55%)	
CCI, n (%)				
0	1,226,052 (70.13%)	249,643 (86.21%)	976,409 (66.94%)	<.001
1	274,493 (15.70%)	18,841 (6.51%)	255,652 (17.53%)	
≥ 2	247,588 (14.16%)	21,092 (7.28%)	226,496 (15.53%)	
Comorbidity, n (%)				
DM	249,273 (14.26%)	16,143 (5.57%)	233,130 (15.98%)	<.001
Hyperlipidemia	507,183 (29.01%)	29,640 (10.24%)	477,543 (32.74%)	<.001
HTN	459,210 (26.27%)	27,778 (9.59%)	431,432 (29.58%)	<.001
COPD	59,009 (3.38%)	5,414 (1.87%)	53,595 (3.67%)	<.001
Prior COVID-19 infection, n (%)	13,719 (0.78%)	2,970 (1.03%)	10,749 (0.74%)	<.001
1st vaccination product, n (%)				
AZD1222	609,023 (41.76%)		609,023 (41.76%)	
BNT162b2	826,953 (56.70%)		826,953 (56.70%)	
mRNA-1273	22,573 (1.55%)		22,573 (1.55%)	
JNJ-78436735	8 (0.00%)		8 (0.00%)	
2nd vaccination product, n (%)				
AZD1222	510,261 (34.98%)		510,261 (34.98%)	
BNT162b2	925,692 (63.47%)		925,692 (63.47%)	
mRNA-1273	22,596 (1.55%)		22,596 (1.55%)	
JNJ-78436735	8 (0.00%)		8 (0.00%)	
1st – 2nd vaccination product, n (%)				
AZD1222 – AZD1222	510,253 (34.98%)		510,253 (34.98%)	
AZD1222 – BNT162b2	98,762 (6.77%)		98,762 (6.77%)	
AZD1222 – mRNA-1273	2 (0.00%)		2 (0.00%)	
AZD1222 – JNJ-78436735	6 (0.00%)		6 (0.00%)	
BNT162b2 – AZD1222	3 (0.00%)		3 (0.00%)	
BNT162b2 – BNT162b2	826,925 (56.69%)		826,925 (56.69%)	
BNT162b2 – mRNA-1273	23 (0.00%)		23 (0.00%)	
BNT162b2 – JNJ-78436735	2 (0.00%)		2 (0.00%)	
mRNA-1273 – BNT162b2	2 (0.00%)		2 (0.00%)	
mRNA-1273 – mRNA-1273	22,571 (1.55%)		22,571 (1.55%)	
JNJ-78436735 – AZD1222	5 (0.00%)		5 (0.00%)	
JNJ-78436735 – BNT162b2	3 (0.00%)		3 (0.00%)	
1st – 2nd vaccination type, n (%)				
No vaccination	289,576 (16.56%)	289,576 (100%)		
Only mRNA vaccine	849,526 (48.60%)		849,526 (58.24%)	
Only cDNA vaccine	510,253 (29.19%)		510,253 (34.98%)	
Heterologous vaccination	98,778 (5.65%)		98,778 (6.77%)	
Vaccination interval, mean (SD), months	50.88 (23.19&)		50.88 (23.19&)	

*All values expressed as mean ± standard deviation. n, number; CCI, Charson's comorbidity index; DM, Diabetic mellitus; HTN, Hypertension; COPD, Chronic obstructive pulmonary diseases; AZD-1222, AstraZeneca ChAdOx1-S recombinant vaccine; BNT162b2, Pfizer-BioNTech Comirnaty; mRNA-1273, Moderna Spikevax; JNJ-78436735, Janssen/Johnson and Johnson COVID-19 Vaccine.

Table 2 Cumulative incidence rate (cIR) of non-fatal immune-related adverse events (irAEs) following COVID-19 vaccination.

Disease	Vaccination	Total number	One week				Two weeks				One month				Three months			
			event	IR	95% CI	*P*	event	cIR	95% CI	*P*	event	cIR	95% CI	*P*	event	cIR	95% CI	*P*
Endometriosis	No	289576	4	0.14	0.00-0.27	.389	13	0.45	0.20-0.69	.877	35	1.21	0.81-1.61	.704	99	3.42	2.75-4.09	0.15
	Yes	1458557	34	0.23	0.15-0.31		63	0.43	0.33-0.54		165	1.13	0.96-1.30		584	4	3.68-4.33	
Menstrual disorder	No	289576	82	2.83	2.22-3.44	.638	161	5.56	4.70-6.42	.096	346	11.95	10.69-13.21	.002	1025	35.4	33.23-37.56	<0.001
	Yes	1458557	442	3.03	2.75-3.31		935	6.41	6.00-6.82		2081	14.27	13.65-14.88		6481	44.43	43.35-45.51	
Bruise	No	289576	4	0.14	0.00-0.27	<.001	6	0.21	0.04-0.37	<.001	11	0.38	0.16-0.60	<.001	48	1.66	1.19-2.13	<0.001
	Yes	1458557	107	0.73	0.59-0.87		181	1.24	1.06-1.42		287	1.97	1.74-2.20		559	3.83	3.51-4.15	
Herpes zoster	No	289576	31	1.07	0.69-1.45	<.001	66	2.28	1.73-2.83	<.001	162	5.59	4.73-6.46	<.001	454	15.68	14.24-17.12	<0.001
	Yes	1458557	472	3.24	2.94-3.53		1055	7.23	6.80-7.67		2270	15.56	14.92-16.20		6575	45.08	43.99-46.17	
Alopecia	No	289576	6	0.21	0.04-0.37	.101	10	0.35	0.13-0.56	.003	23	0.79	0.47-1.12	<.001	80	2.76	2.16-3.37	<0.001
	Yes	1458557	61	0.42	0.31-0.52		122	0.84	0.69-0.98		266	1.82	1.60-2.04		766	5.25	4.88-5.62	
Warts	No	289576	20	0.69	0.39-0.99	.279	30	1.04	0.67-1.41	<.001	78	2.69	2.10-3.29	<.001	197	6.8	5.85-7.75	<0.001
	Yes	1458557	135	0.93	0.77-1.08		303	2.08	1.84-2.31		658	4.51	4.17-4.86		1811	12.42	11.84-12.99	
Visual impairment	No	289576	0	0	0.00-0.00	1	0	0	0.00-0.00	.372	0	0	0.00-0.00	.024	2	0.07	0.00-0.16	0.008
	Yes	1458557	5	0.03	0.00-0.06		9	0.06	0.02-0.10		23	0.16	0.09-0.22		50	0.34	0.25-0.44	
Glaucoma	No	289576	43	1.48	1.04-1.93	<.001	80	2.76	2.16-3.37	<.001	199	6.87	5.92-7.83	<.001	534	18.44	16.88-20.00	<0.001
	Yes	1458557	430	2.95	2.67-3.23		901	6.18	5.77-6.58		1892	12.97	12.39-13.56		5749	39.42	38.40-40.43	
Tinnitus	No	289576	11	0.38	0.16-0.60	.013	26	0.9	0.55-1.24	.003	54	1.86	1.37-2.36	<.001	171	5.91	5.02-6.79	<0.001
	Yes	1458557	119	0.82	0.67-0.96		237	1.62	1.42-1.83		534	3.66	3.35-3.97		1789	12.27	11.70-12.83	
Inner ear disease	No	289576	43	1.48	1.04-1.93	<.001	71	2.45	1.88-3.02	<.001	152	5.25	4.41-6.08	<.001	466	16.09	14.63-17.55	<0.001
	Yes	1458557	553	3.79	3.48-4.11		1094	7.5	7.06-7.94		2381	16.32	15.67-16.98		6870	47.1	45.99-48.21	
Middle ear disease	No	289576	14	0.48	0.23-0.74	<.001	42	1.45	1.01-1.89	<.001	93	3.21	2.56-3.86	<.001	290	10.01	8.86-11.17	<0.001
	Yes	1458557	218	1.49	1.30-1.69		468	3.21	2.92-3.50		1058	7.25	6.82-7.69		3343	22.92	22.14-23.70	
Other ear disease	No	289576	43	1.48	1.04-1.93	<.001	86	2.97	2.34-3.60	<.001	202	6.98	6.01-7.94	<.001	607	20.96	19.30-22.63	<0.001
	Yes	1458557	550	3.77	3.46-4.09		1112	7.62	7.18-8.07		2441	16.74	16.07-17.40		7552	51.78	50.61-52.94	
Periodontal disease	No	289576	5	0.17	0.02-0.32	1	6	0.21	0.04-0.37	.044	14	0.48	0.23-0.74	.001	31	1.07	0.69-1.45	<0.001
	Yes	1458557	30	0.21	0.13-0.28		70	0.48	0.37-0.59		160	1.1	0.93-1.27		488	3.35	3.05-3.64	

Cumulative incidence rates were calculated as a rate per 10,000 individuals. IR, incidence rate; CI, confidence interval; cIR, cumulative incidence.


50% of the population residing in Seoul from NHIS database at 1, January, 2021 (n = 4,348,412)
Excluded
age < 20 years (n = 144,525)
Subjects (n = 4,203,887)
COVID-19 Vaccination
Vaccination (+) (n = 3,839,014)
Vaccination (-) (n = 364,873)
Deaths or subjects who received second dose (n = 1,684,625)
Excluded
Excluded
Deaths (n = 13,890)
Vaccinated subjects at 30, September, 2021 (n = 2,154,389)
Non-vaccinated subjects at 1, October, 2021 (n = 350,983)
Underlying disease
Endometriosis (n = 15,778)
Menstruation (n = 21,609)
Abnormal bleeding (n = 77,896)
Bruise (n = 13,699)
Zoster (n = 68,311)
Alopecia (n = 9,018)
Warts (n = 21,826)
Bruise (n = 13,699)
Visual impairment (n = 5,304)
Glaucoma (n = 357,156)
Inner ear (n = 158,386)
Middle ear (n = 78,007)
Other ear (n = 119,016)
Periodonal disease (n = 9,022)
Excluded
Excluded
Underlying disease
Endometriosis (n = 2,634)
Menstruation (n = 4,396)
Abnormal bleeding (n = 15,433)
Bruise (n = 1,707)
Zoster (n = 5,584)
Alopecia (n = 1,707)
Warts (n = 2,634)
Bruise (n = 1,707)
Visual impairment (n = 403)
Glaucoma (n = 24,151)
Inner ear (n = 11,299)
Middle ear (n = 6,310)
Other ear (n = 8,751)
Periodonal disease (n = 795)
Vaccinated subjects (n = 1,458,557)
Non-vaccinated subjects (n = 289,579)


Endometriosis
Menstrual disorders
Bruise
Zoster
Alopecia
Warts
Visual impairment
Glaucoma
Tinnitus
Inner ear
Middle ear
Other ear
Periodontal disease
2
4
6
8
10
12
14
16
a
Hazard Ratio (95% Confidence Interval)
Endometriosis (1 week)
Endometriosis (2 weeks)
Endometriosis (1 month)
Endometriosis (3 months)
Menstural disorders (1 week)
Menstural disorders (2 weeks)
Menstural disorders (1 month)
Menstural disorders (3 months)
Bruise (1 week)
Bruise (2 weeks)
Bruise (1 month)
Bruise (3 months)
Zoster (1 week)
Zoster (2 weeks)
Zoster (1 month)
Zoster (3 months)
Alopecia (1 week)
Alopecia (2 weeks)
Alopecia (1 month)
Alopecia (3 months)
Warts (1 week)
Warts (2 weeks)
Warts (1 month)
Warts (3 months)
Visual impairment (3 months)
Glaucoma (1 week)
Glaucoma (2 weeks)
Glaucoma (1 month)
Glaucoma (3 months)
Tinnitus (1 week)
Tinnitus (2 weeks)
Tinnitus (1 month)
Tinnitus (3 months)
Inner ear (1 week)
Inner ear (2 weeks)
Inner ear (1 month)
Inner ear (3 months)
Middle ear (1 week)
Middle ear (2 weeks)
Middle ear (1 month)
Middle ear (3 months)
Other ear (1 week)
Other ear (2 weeks)
Other ear (1 month)
Other ear (3 months)
Periodontal disease (1 week)
Periodontal disease (2 weeks)
Periodontal disease (1 month)
Periodontal disease (3 months)
0
2
4
6
8
10
12
14
16
b
Odds Ratio (95% Confidence Interval)


Endometriosis (mRNA)
Endometriosis (cDNA)
Endometriosis (heterologous)
Menstrual disorders (mRNA)
Menstrual disorders (cDNA)
Menstrual disorders (heterologous)
Bruise (mRNA)
Bruise (cDNA)
Bruise (heterologous)
Zoster (mRNA)
Zoster (cDNA)
Zoster (heterologous)
Alopecia (mRNA)
Alopecia (cDNA)
Alopecia (heterologous)
Warts (mRNA)
Warts (cDNA)
Warts (heterologous)
Visual impairment (mRNA)
Visual impairment (cDNA)
Visual impairment (heterologous)
Glaucoma (mRNA)
Glaucoma (cDNA)
Glaucoma (heterologous)
Tinnitus (mRNA)
Tinnitus (cDNA)
Tinnitus (heterologous)
Inner ear (mRNA)
Inner ear (cDNA)
Inner ear (heterologous)
Middle ear (mRNA)
Middle ear (cDNA)
Middle ear (heterologous)
Other ear (mRNA)
Other ear (cDNA)
Other ear (heterologous)
Periodontal disease (mRNA)
Periodontal disease (cDNA)
Periodontal disease (heterologous)
0
5
10
15
20
25
30
Hazard Ratio (95% Confidence Interval)
a


Disease
Time Interval
1 week
2 weeks
1 month
3 months
Endometriosis, mRNA 2.26 1.29 1.23 1.60*
Endometriosis, cDNA 2.42 1.36 1.14 1.08
Endometriosis, heterologous 3.28 1.77 1.75 2.79*
Menstrual disorders, mRNA 1.69* 1.78* 1.87* 2.03*
Menstrual disorders, cDNA 1.35 1.54* 1.45* 1.46*
Menstrual disorders, heterologous 2.01* 2.58* 2.86* 2.86*
Bruise, mRNA 4.34* 4.20* 3.77* 1.77*
Bruise, cDNA 5.77* 6.26* 5.00* 1.88*
Bruise, heterologous 2.66 3.52* 3.46* 1.90*
Zoster, mRNA 2.38* 2.47* 2.10* 2.21*
Zoster, cDNA 3.12* 3.00* 2.53* 2.48*
Zoster, heterologous 1.87* 2.50* 2.65* 2.92*
Alopecia, mRNA 2.72* 3.20* 2.90* 2.31*
Alopecia, cDNA 2.44 2.65* 2.53* 2.25*
Alopecia, heterologous 3.74* 3.72* 3.69* 3.42*
Warts, mRNA 1.69* 2.37* 2.08* 2.22*
Warts, cDNA 1.66 2.26* 2.16* 2.58*
Warts, heterologous 1.86 2.66* 2.03* 2.35*
Visual impairment, mRNA 2.83
Visual impairment, cDNA 6.73*
Visual impairment, heterologous 2.91
Glaucoma, mRNA 1.47* 1.63* 1.41* 1.66*
Glaucoma, cDNA 1.77* 1.98* 1.60* 1.82*
Glaucoma, heterologous 1.69* 2.23* 1.81* 1.84*
Tinnitus, mRNA 2.02* 1.62* 1.80* 1.79*
Tinnitus, cDNA 1.75 1.49 1.58* 1.86*
Tinnitus, heterologous 0.80 0.80 1.24 1.50*
Inner ear, mRNA 2.15* 2.48* 2.53* 2.38*
Inner ear, cDNA 2.35* 2.78* 2.71* 2.46*
Inner ear, heterologous 2.28* 2.28* 2.25* 2.12*
Middle ear, mRNA 2.78* 2.16* 2.17* 2.25*
Middle ear, cDNA 2.75* 1.92* 2.07* 2.18*
Middle ear, heterologous 2.23* 1.74* 1.93* 2.11*
Other ear, mRNA 2.08* 2.13* 2.00* 2.02*
Other ear, cDNA 1.63* 1.70* 1.58* 1.77*
Other ear, heterologous 1.95* 1.72* 1.60* 1.77*
Periodontal disease, mRNA 0.67 1.23 1.28 1.86*
Periodontal disease, cDNA 1.41 2.25 1.99* 2.22*
Periodontal disease, heterologous 1.26 3.73* 3.00* 3.60*
Odds Ratio (OR)
6
5
4
3
2
1
b